These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23292014)

  • 1. [Computational study on prediction of bioactivity for regulation of new designer drugs].
    Kurihara M
    Yakugaku Zasshi; 2013; 133(1):13-6. PubMed ID: 23292014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Computational study on drug design and prediction of bioactivity for regulation of non-controlled psychotropic substances].
    Kurihara M
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):29-33. PubMed ID: 21381392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cocaine-stimulus generalization to two new designer drugs: methcathinone and 4-methylaminorex.
    Young R; Glennon RA
    Pharmacol Biochem Behav; 1993 May; 45(1):229-31. PubMed ID: 8516363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decoding the Structure of Abuse Potential for New Psychoactive Substances: Structure-Activity Relationships for Abuse-Related Effects of 4-Substituted Methcathinone Analogs.
    Negus SS; Banks ML
    Curr Top Behav Neurosci; 2017; 32():119-131. PubMed ID: 27696217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevalence of new designer drugs and their legal status in Japan].
    Kikura-Hanajiri R; Uchiyama N; Kawamura M; Ogata J; Goda Y
    Yakugaku Zasshi; 2013; 133(1):31-40. PubMed ID: 23292017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survey of current trends in the abuse of psychotropic substances and plants in Japan.
    Kikura-Hanajiri R; Uchiyama N; Goda Y
    Leg Med (Tokyo); 2011 May; 13(3):109-15. PubMed ID: 21377397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public Health Risk of Designer Psychotropic Drugs: Should PHASE Be Phased In?
    Greenblatt DJ
    Clin Pharmacol Ther; 2019 Dec; 106(6):1175-1176. PubMed ID: 31441050
    [No Abstract]   [Full Text] [Related]  

  • 8. The synthetic cathinone α-pyrrolidinovalerophenone (α-PVP): pharmacokinetic and pharmacodynamic clinical and forensic aspects.
    Nóbrega L; Dinis-Oliveira RJ
    Drug Metab Rev; 2018 May; 50(2):125-139. PubMed ID: 29540067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food".
    Coppola M; Mondola R
    Toxicol Lett; 2012 Jun; 211(2):144-9. PubMed ID: 22459606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
    Liechti M
    Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In silico study on prediction of bioactivity for regulation of new designer drugs].
    Kurihara M
    Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):315-20. PubMed ID: 26657122
    [No Abstract]   [Full Text] [Related]  

  • 12. Designer Benzodiazepines: Another Class of New Psychoactive Substances.
    Moosmann B; Auwärter V
    Handb Exp Pharmacol; 2018; 252():383-410. PubMed ID: 30367253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designer Drugs 2.0.
    Huestis MA; Tyndale RF
    Clin Pharmacol Ther; 2017 Feb; 101(2):152-157. PubMed ID: 28084644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deconstructing Designer Drugs.
    Sellers EM
    Clin Pharmacol Ther; 2017 Feb; 101(2):167-169. PubMed ID: 27564430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues.
    Sakloth F; Kolanos R; Mosier PD; Bonano JS; Banks ML; Partilla JS; Baumann MH; Negus SS; Glennon RA
    Br J Pharmacol; 2015 May; 172(9):2210-8. PubMed ID: 25522019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designer psychostimulants: pharmacology and differences.
    Iversen L; White M; Treble R
    Neuropharmacology; 2014 Dec; 87():59-65. PubMed ID: 24456744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methcathinone and 3-Fluoromethcathinone Stimulate Spontaneous Horizontal Locomotor Activity in Mice and Elevate Extracellular Dopamine and Serotonin Levels in the Mouse Striatum.
    Wojcieszak J; Andrzejczak D; Wojtas A; Gołembiowska K; Zawilska JB
    Neurotox Res; 2019 Apr; 35(3):594-605. PubMed ID: 30377956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products.
    Uchiyama N; Matsuda S; Kawamura M; Shimokawa Y; Kikura-Hanajiri R; Aritake K; Urade Y; Goda Y
    Forensic Sci Int; 2014 Oct; 243():1-13. PubMed ID: 24769262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designer drugs 2015: assessment and management.
    Weaver MF; Hopper JA; Gunderson EW
    Addict Sci Clin Pract; 2015 Mar; 10(1):8. PubMed ID: 25928069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research Status of New Designer Drug Methcathinone in Forensic Toxicology.
    Deng YF; Liu L; Yang ZX; Liang M
    Fa Yi Xue Za Zhi; 2018 Jun; 34(6):611-616. PubMed ID: 30896098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.